Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | UGCG | Q16739 | 2/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL581027 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL879887 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL1309167 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL517888 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL31490075 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL7564811 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL580258 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL850609 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL5619569 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL5857276 | 0.98 | L3MBTL1 (0.53) | L3MBTL1TDP1TSHRHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117913367-A | Preparation method of composite organic solvent, electrolyte and lithium-sulfur battery | 东方电气集团科学技术研究院有限公司 | 2024-04-19 | — | — | CN | claimed |
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622891-B2 | AMP-activated protein kinase activator | KYOTO PHARMACEUTICAL UNIVERSITY (JP) | 2026-05-12 | — | — | US | disclosed |
| US-20260102348-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORPORATION (JP) | 2026-04-16 | — | — | US | disclosed |
| US-20260098209-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL CURED LAYER, OPTICAL FILM, POLARIZING PLATE, AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2026-04-09 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12508226-B2 | Lipid composition | FUJIFILM CORPORATION (JP) | 2025-12-30 | — | — | US | disclosed |
| US-12370143-B2 | Compound or salt thereof and lipid particles | FUJIFILM CORPORATION (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4328309-B1 | LIPID COMPOSITION | FUJIFILM CORP (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-0338887-B1 | Phosphonoalkylpurine derivatives | MERRELL DOW PHARMA (US) | 1993-12-08 | — | — | EP | disclosed |
| US-5243076-A | Adrenergic stimulant intermediates | GLAXO GROUP LTD. | 1993-09-07 | — | — | US | disclosed |
| US-5225445-A | Respiratory system disorders | GLAXO GROUP LTD. | 1993-07-06 | — | — | US | disclosed |
| WO-1993001196-A1 | KETOALKYLGLYCEROPHOSPHOLIPIDS HAVING ANTITUMOR AND ANTI-PLATELET AGGREGATION ACTIVITIES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFROM | LABORATORIOS MENARINI S.A. (ES) | 1993-01-21 | — | — | WO | disclosed |
| US-5126375-A | Asthma, chronic bronchitis | GLAXO GROUP LTD. (GB) | 1992-06-30 | — | — | US | disclosed |
| US-5091422-A | Treating inflammatory or allergic skin disease, lowering gastric acidity | GLAXO GROUP LIMITED (GB) | 1992-02-25 | — | — | US | disclosed |
| US-4992474-A | Adrenergic stimulants | GLAXO GROUP LTD. (GB) | 1991-02-12 | — | — | US | disclosed |
| CN-1037342-A | Phosphonoalkylpurinederivatives derivatives | MERRELL DOW PHARMA (US) | 1989-11-22 | — | — | CN | disclosed |
| EP-0338168-A1 | Phosphonoalkylpurine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-25 | — | — | EP | disclosed |
| EP-0338887-A1 | Phosphonoalkylpurine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098209-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL CURED LAYER, OPTICAL FILM, POLARIZING PLATE, AND IMAGE DISPLAY DEVICE | SOS1, BMP2, SCP2 | L3MBTL1 1245/4885TDP1 4037/4885TSHR 2928/4885 |
| US-12370143-B2 | Compound or salt thereof and lipid particles | NR1H3, NR1H2, LDLR | L3MBTL1 1766/4885TDP1 3943/4885TSHR 999/4885 |
| US-20260102348-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | LDLR, NR1H3, NR1H2 | L3MBTL1 628/4885TDP1 3096/4885TSHR 1103/4885 |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | GPR119, GLP1R, GPR65 | L3MBTL1 4809/4885TDP1 4710/4885TSHR 1353/4885 |
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KRAS, HRAS, BCL6 | L3MBTL1 574/4885TDP1 2369/4885TSHR 371/4885 |
| US-12622891-B2 | AMP-activated protein kinase activator | PRKAA1, PRKAG1, PRKAB1 | L3MBTL1 1429/4885TDP1 2068/4885TSHR 1908/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | L3MBTL1 539/4885TDP1 1778/4885TSHR 2915/4885 |
| US-12508226-B2 | Lipid composition | APOB, NAF1, SLC27A1 | L3MBTL1 460/4885TDP1 2967/4885TSHR 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.